Strategy for Identifying Rational Sensitivity Analysis Using PBPK Modeling for Precipitant Drug–Drug Interaction Predictions

Physiology Based Pharmacokinetic (PBPK) modeling is an established essential tool for predicting and/or analyzing drug-drug interactions (DDI). Uncertainty and variability associated with in vitro determined DDI-related parameters have often been considered a limitation for predicting PBPK-DDIs. Sensitivity analysis (SA) around DDI input parameters using PBPK analysis is often applied for assessing the relevance of clinical DDI predictions/prioritization/study designs. This perspective aims to explore and advocate practical approaches for precipitant (inhibitor/inducer) PBPK-DDI SA for optimal clinically relevant evaluations.

Authors

Institutions

Publication Details

Journal
Clinical Pharmacology & Therapeutics
Published
2025-11-13
DOI
https://doi.org/10.1002/cpt.70127
Primary Topic
Pharmacogenetics and Drug Metabolism
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Strategy for Identifying Rational Sensitivity Analysis Using PBPK Modeling for Precipitant Drug–Drug Interaction Predictions

Pradeep Kumar Sharma, Karen Rowland Yeo, Kunal S. Taskar
Clinical Pharmacology & Therapeutics
Pharmacogenetics and Drug Metabolism
article

Strategy for Identifying Rational Sensitivity Analysis Using PBPK Modeling for Precipitant Drug–Drug Interaction Predictions

Pradeep Kumar Sharma, Karen Rowland Yeo, Kunal S. Taskar
article en

Abstract

Physiology Based Pharmacokinetic (PBPK) modeling is an established essential tool for predicting and/or analyzing drug-drug interactions (DDI). Uncertainty and variability associated with in vitro determined DDI-related parameters have often been considered a limitation for predicting PBPK-DDIs. Sensitivity analysis (SA) around DDI input parameters using PBPK analysis is often applied for assessing the relevance of clinical DDI predictions/prioritization/study designs. This perspective aims to explore and advocate practical approaches for precipitant (inhibitor/inducer) PBPK-DDI SA for optimal clinically relevant evaluations.

Clinical Pharmacology & TherapeuticsVol. 119(2)
AstraZeneca (United Kingdom) (GB), Age UK (GB), Certara (United States) (US), AstraZeneca (Poland) (PL)
AstraZeneca
Openalex Percentile: Top 57%
Pharmacogenetics and Drug Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Strategy for Identifying Rational Sensitivity Analysis Using PBPK Modeling for Precipitant Drug–Drug Interaction Predictions — Pradeep Kumar Sharma, Karen Rowland Yeo, et al. · Clinical Pharmacology & Therapeutics (2025) | TGRS Research Map | TGRS